Leukocyte adhesion deficiency type 1 (LAD-1) is a rare inherited disorder characterized by impaired ability of leukocytes (white blood cells) to adhere to vascular endothelium and migrate to sites of inflammation. This condition is caused by deficiency or absence of integrins, which are necessary for leukocyte adhesion. As a result, patients with LAD-1 experience frequent bacterial infections, which can lead to severe complications and, in some cases, death. Limited ability to biocenosis and protection against infections significantly reduces the quality of life of such patients, which requires a comprehensive approach to diagnosis and treatment.
History of the disease and interesting historical facts
The disease was first described in 1982, when unusual infections that did not respond to standard treatment were detected in children. The discovery of the role of integrins in the process of cell adhesion became a key moment in understanding the pathogenesis of this pathology. An interesting fact is that until the 1990s, DAL-1 was almost completely unknown to the general medical community, and only with the development of molecular genetics and new diagnostic methods did it become possible to accurately identify this disease.
Epidemiology
Leukocyte adhesion deficiency type 1 is very rare, with an incidence of approximately 1 in 1,000,000 live births. There are reports of higher incidences in certain ethnic groups, including Jewish populations. It is important to note that statistics may vary by region, requiring further research to better understand the epidemiology.
Genetic predisposition to this disease
DAL-1 is a hereditary disease transmitted in an autosomal recessive manner. The main culprits in the development of the disease are the ITGB2 genes located on chromosome 21, which encode beta-2 integrin. Mutations in this gene result in failure of integrin synthesis, which interferes with the normal function of leukocytes. Often identified mutations are deletions and point mutations, which emphasizes the importance of genetic testing for early diagnosis.
Risk factors for the development of this disease
Patients with DAL-1 most often have a hereditary predisposition, but certain environmental factors can worsen the course of the disease. The main risk factors include:
- Genetic mutations in families with a history of blood disorders.
- Existing infectious diseases in the mother during pregnancy.
- Pathologies affecting the immune system.
Diagnosis of this disease
DAL-1 diagnostics includes several methods:
- Main symptoms: recurrent infections, protracted inflammatory processes, most often caused by bacterial flora.
- Laboratory tests: blood tests to detect leukocytes, leukocyte adhesion tests.
- Radiological examinations: computed tomography to assess the condition of organs susceptible to infection.
- Other types of diagnostics: genetic testing to confirm the diagnosis.
- Differential diagnosis: exclusion of other immunodeficiency conditions.
Treatment
Treatment of DAL-1 should be comprehensive and individualized. Main directions:
- General treatment: consultations with immunologists, regular follow-up examinations.
- Pharmacological treatment: antibacterial drugs based on clinical need.
- Surgical treatment: operations to drain purulent foci.
- Other treatments: therapy with vasodilators to improve microcirculation.
List of medications used to treat this disease
The main drugs used to treat DAL-1 include:
- Antibiotics (eg, cephalosporins, penicillins).
- Immunomodulators (eg, interferons).
- Steroid anti-inflammatory drugs.
Disease monitoring
DAL-1 monitoring includes:
- Regular monitoring of the patient's condition, control of the level of leukocytes.
- Prognosis: depends on the timeliness and adequacy of treatment, but may be unfavorable in the absence of therapy.
- Complications: Recurrent infections can lead to serious consequences such as sepsis.
Age-related features of the disease
The course of DAL-1 can vary significantly depending on the patient's age. In newborns, the disease may manifest itself in the form of frequent infections, while in adolescence, a more severe course with multiple complications may be observed. In older patients, the risk of complications also increases due to concomitant diseases and age-related changes in the immune system.
Questions and Answers
- What is leukocyte adhesion deficiency type 1? This is a rare inherited disorder in which white blood cells fail to attach normally to the vascular endothelium, leading to frequent infections.
- How to diagnose DAL-1? Diagnosis includes blood tests, leukocyte adhesion tests, and genetic testing.
- What are the main treatment methods? Treatment includes antibiotics, immunomodulators and, if necessary, surgery.
- What is the prognosis for patients with DAL-1? The prognosis depends on timely treatment, but the disease can have serious consequences.
- What are the risk factors for DAL-1? The main risk factors are genetic predisposition, as well as infectious diseases in the mother during pregnancy.
Advice from Dr. Oleg Korzhikov
Dr. Korzhikov recommends that patients with DAL-1 pay special attention to infection prevention:
- Get vaccinated regularly, especially against influenza and pneumococcal infection.
- Observe personal hygiene rules and avoid contact with people who have signs of infectious diseases.
- Monitor your health and consult a doctor if the first symptoms appear.
